Global Information
회사소개 | 문의 | 비교리스트

조루증 : 파이프라인 리뷰

Premature Ejaculation - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 232828
페이지 정보 영문 41 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


조루증 : 파이프라인 리뷰 Premature Ejaculation - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 41 Pages

조루증은 가장 일반적인 남성의 성기능 장애입니다. 사정은 중추신경계에 의해 조절되며, 성적 자극 및 마찰에 의해 척수를 통해 뇌에 전기신호가 전달되면 일어납니다. 소인으로는 발기부전, 심리적 스트레스, 뇌내 화학전달물질의 활동에 영향을 미치는 특정 약물의 섭취 등이 있습니다. 치료에는 표면마취제 크림 및 항우울제 등이 사용됩니다.

조루증 치료제의 개발 상황에 대해 조사했으며, 파이프라인 제품의 개요, 임상시험 단계별 제품 개요, 주요 기업의 개요, 약제 개요, 파이프라인 제품의 최신 동향 등을 정리하여 전해드립니다.

서론

  • 조사 범위

조루증 개요

치료제 개발

  • 파이프라인 제품의 개요
  • 기업별 파이프라인 제품
  • 기업에서 개발중인 제품

조루증 : 치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

조루증 치료제 개발에 참여하고 있는 기업

  • Allergan Plc
  • Ixchelsis Ltd
  • NeuroHealing Pharmaceuticals Inc
  • Plethora Solutions Holdings Plc
  • SK Chemicals Co Ltd

약제 개요

  • (lidocaine + prilocaine)
  • IX-01
  • modafinil
  • NCE-405
  • onabotulinumtoxin A

조루증 : 휴지중인 프로젝트

조루증 : 개발이 중지된 제품

조루증 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

KSA 17.06.20

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Premature Ejaculation, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Premature Ejaculation - Pipeline by Ctcbio Inc, H1 2020
  • Premature Ejaculation - Pipeline by Dicot AB, H1 2020
  • Premature Ejaculation - Pipeline by Ixchelsis Ltd, H1 2020
  • Premature Ejaculation - Pipeline by NeuroHealing Pharmaceuticals Inc, H1 2020
  • Premature Ejaculation - Pipeline by Plethora Solutions Holdings Plc, H1 2020
  • Premature Ejaculation - Dormant Projects, H1 2020
  • Premature Ejaculation - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Premature Ejaculation, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Premature Ejaculation - Pipeline Review, H1 2020, provides an overview of the Premature Ejaculation (Male Health) pipeline landscape.

Premature ejaculation (PE) is also known as rapid ejaculation, is the most common type of sexual dysfunction in men. Ejaculation is controlled by the central nervous system. This happens when sexual stimulation and friction provide impulses that are delivered to the spinal cord and into the brain. The predisposing factors include erectile dysfunction, stress and certain medications that influence the action of chemical messengers in the brain (psychotropics) may contribute to premature ejaculation. Treatment includes topical anesthetic creams and antidepressants.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Premature Ejaculation - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Premature Ejaculation (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Premature Ejaculation (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Premature Ejaculation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively.

Premature Ejaculation (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Premature Ejaculation (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Premature Ejaculation (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Premature Ejaculation (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Premature Ejaculation (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Premature Ejaculation (Male Health)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Premature Ejaculation (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Premature Ejaculation (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Premature Ejaculation - Overview
    • Premature Ejaculation - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Premature Ejaculation - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Premature Ejaculation - Companies Involved in Therapeutics Development
    • Ctcbio Inc
    • Dicot AB
    • Ixchelsis Ltd
    • NeuroHealing Pharmaceuticals Inc
    • Plethora Solutions Holdings Plc
  • Premature Ejaculation - Drug Profiles
    • (clomipramine hydrochloride + sildenafil citrate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (lidocaine + prilocaine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cligosiban - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • libiguins - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • modafinil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Premature Ejaculation - Dormant Projects
  • Premature Ejaculation - Discontinued Products
  • Premature Ejaculation - Product Development Milestones
    • Featured News & Press Releases
      • Sep 19, 2019: Plethora Pharma Solutions receives CHMP positive opinion for Senstend
      • Jul 11, 2018: Dicot signs extended Service Agreement with Anthem Biosciences for Preclinical Development of Libiguin
      • Jan 25, 2016: Ixchelsis Announces Positive Clinical Proof of Concept Results for IX-01 in Treating Premature Ejaculation
      • Nov 11, 2014: Plethora Solutions Provides Company Update
      • Oct 07, 2014: PSD502 To Be Marketed As Fortacin Throughout The EU
      • Mar 26, 2014: Plethora Solutions Announces Manufacturing Appointment
      • Mar 11, 2014: Plethora Solutions Provides Company update
      • Nov 19, 2013: Plethora Solutions Receives European Commission Approval For PSD502 To Treat Premature Ejaculation
      • Sep 19, 2013: Plethora Solutions Receives CHMP Positive Opinion For Lidocaine/Prilocaine Plethora For Treatment Of Primary Premature Ejaculation
      • Jul 01, 2013: AGM Statement & PSD502 Regulatory Update
      • Jun 11, 2012: Plethora Provides PSD502 Regulatory Submission Update
      • Mar 15, 2012: Plethora Provides Update On Regulatory Submission Of PSD502
      • Dec 19, 2011: Plethora Provides Update On PSD502
      • Jun 01, 2010: Shionogi Pharma Presents Data On PSD502 For Primary Premature Ejaculation
      • May 26, 2010: Shionogi Pharma Announces Five Clinical Presentations On PSD502 For Primary Premature Ejaculation At AUA Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q